Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 17/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.50 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.46 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770698 | 0.95 | HSP90AB1 (0.48) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL7813344 | 0.88 | CYP2C19 (0.46) | HSP90AB1HSP90AA1HDAC1CYP2C19 | |
| SCHEMBL14227939 | 0.83 | HSP90AB1 (0.43) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL28439303 | 0.82 | ADORA2A (0.37) | HSP90AB1HSP90AA1 | |
| SCHEMBL6322265 | 0.81 | CYP2C19 (0.47) | HSP90AB1HSP90AA1CYP2C19 | |
| SCHEMBL7816738 | 0.81 | KDM4E (0.56) | HSP90AB1HSP90AA1HDAC6CYP2C19 | |
| SCHEMBL13645718 | 0.81 | HSP90AB1 (0.51) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL8649570 | 0.80 | HSP90AB1 (0.55) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL9116660 | 0.80 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 | |
| SCHEMBL10917478 | 0.80 | HSP90AB1 (0.50) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110713490-A | Preparation method of penciclovir | 浙江医药股份有限公司新昌制药厂 | 2020-01-21 | — | — | CN | claimed |
| CN-112979653-A | Method for synthesizing famciclovir by using microchannel reactor | 上药康丽（常州）药业有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-108314685-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-108484605-B | Preparation method of 2-amino-6-chloro-9- (4-acetoxyl-3-acetoxymethyl butyl) purine | 上药康丽（常州）药业有限公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-110713490-A | Preparation method of penciclovir | 浙江医药股份有限公司新昌制药厂 | 2020-01-21 | — | — | CN | disclosed |
| CN-101195622-A | Process for the preparation of famciclovir | FANGXIA ENTPR INF CONSULT CO (CN) | 2008-06-11 | — | — | CN | disclosed |
| US-7355043-B2 | Preparation of purines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-04-08 | — | — | US | disclosed |
| EP-1068209-B1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR | NOVARTIS INT PHARM LTD (BM) | 2005-09-14 | — | — | EP | disclosed |
| EP-1068210-B1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES | NOVARTIS INT PHARM LTD (BM) | 2004-06-02 | — | — | EP | disclosed |
| US-20030130512-A1 | Process for the production of purine derivatives and intermediates therefor | DPT LABORATORIES, LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6437125-B1 | REARRANGEMENT OF N-7 ALKYL GROUP TO THE N-9; PALLADIUM CATALYST AND A (DIPHENYLPHOSPHINO)ALKANE; PENCICLOVIR AND FAMCICLOVIR | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2002-08-20 | — | — | US | disclosed |
| EP-1068209-A1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR | SMITHKLINE BEECHAM PLC (GB) | 2001-01-17 | — | — | EP | disclosed |
| EP-1068210-A2 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051604-A2 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051603-A1 | PROCESS FOR THE PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR | SMITHKLINE BEECHAM PLC (GB) | 1999-10-14 | — | — | WO | disclosed |
| EP-0302644-B1 | Purine compounds and their preparation | BEECHAM GROUP PLC (GB) | 1997-01-29 | — | — | EP | disclosed |
| US-5175288-A | Process for preparing purine derivatives and intermediates thereof | BEECHAM GROUP P.L.C. (GB) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130512-A1 | Process for the production of purine derivatives and intermediates therefor | TYMP, DPYD, PNP | HSP90AB1 4738/4885HSP90AA1 4716/4885HSP90B1 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.